2026-05-13 · 2026-05 / week-1

Exelixis Still Prices Cabometyx, Not the Next Franchise

Exelixis Still Prices Cabometyx, Not the Next Franchise

Summary: EXEL last traded at $49.46 at 18:00 Ho Chi Minh City time on May 13, 2026. On May 5, 2026, Exelixis reported $610.8 million of first-quarter revenue, $0.87 non-GAAP diluted EPS, kept 2026 total-revenue guidance at $2.525 billion to $2.625 billion while explicitly excluding any revenue from a potential U.S. approval of zanzalintinib, said it expects to finish the remaining $159.4 million of its October 2025 repurchase program in May, and authorized another $750 million of repurchases through December 2027. By simple arithmetic, at today's price the remaining authorization across both programs equals about 18.4 million shares, or roughly 7.3% of the April 27 share count. The stock still trades like Cabometyx is a mature franchise and the rest is optional noise.

Opportunity Ranking

Rank Idea Discovery Lane Why It May Be Best Now Evidence Freshness Catalyst Window Asymmetry Main Reason to Reject
1 Exelixis still prices Cabometyx, not the next franchise U.S. large-cap biotech / buyback compounder / oncology catalyst EXEL last traded at $49.46 after Q1 revenue of $610.8 million, non-GAAP diluted EPS of $0.87, unchanged 2026 revenue guidance of $2.525 billion to $2.625 billion that excludes any zanzalintinib launch revenue, and a remaining $909.4 million of authorized repurchases across two programs. Official May 5, 2026 results and 10-Q, plus live May 13 market snapshot. Remainder of the October 2025 buyback is expected to finish in May 2026; STELLAR-303 final analysis is expected in mid-2026; STELLAR-304 topline is expected in second half 2026; zanzalintinib PDUFA date is December 3, 2026. Liquid stock, visible share shrink, cash-heavy balance sheet, and a regulatory clock that management's revenue guide still excludes. Biotech names can stay capped if investors refuse to underwrite clinical and regulatory bridge value before approval.
2 Baidu still trades legacy search, not the return package Broader Asia / China ADR / AI transition / capital return BIDU last traded at $139.94 ahead of May 18, 2026 Q1 results after authorizing a new $5.0 billion buyback, approving its first dividend policy, and reporting Q4 AI Cloud Infra revenue of RMB 5.8 billion. Official February 26 and April 23, 2026 releases, plus live May 13 market snapshot. Q1 results on May 18, 2026, AGM on June 5, 2026, and potential first dividend payment later in 2026. The return package is real and the event calendar is near. The valuation bridge still requires more inference around China discount, AI monetization durability, and governance risk than the best idea today.
3 Nomura posted the record year, but the buyback clock is slowing Japan financial / capital return / below-book rerating NMR last traded at $7.90 after Nomura reported record full-year net income of JPY 362.1 billion, 10.1% ROE, a JPY 51 annual dividend, and a JPY 60 billion buyback authorization that runs through September 30, 2026. Official January 30, April 15, and April 24, 2026 releases, plus live May 13 market snapshot. Ongoing buyback status releases, dividend follow-through, and next quarterly print. Below-book valuation plus capital return is real. The main surprise has already printed, and the repurchase pace is too gradual to beat Exelixis on timing.
4 RELX keeps shrinking, but the market already pays for quality Europe / UK information services / active buyback / quality compounder RELX last traded at $32.77 after reporting 128.5p adjusted EPS, a 67.5p full-year dividend, and a planned GBP 2.25 billion 2026 buyback, with GBP 250 million already completed, while the April 23 trading update reaffirmed outlook. Official February 12 and April 23, 2026 company releases, plus live May 13 market snapshot. Ongoing 2026 buyback execution and first-half 2026 results. Real share shrink inside a durable business. The business is excellent, but the tape already pays a quality-compounder multiple, so the disagreement is smaller.

Selected opportunity: Exelixis still prices Cabometyx, not the next franchise.

Why this one now: It has the cleanest combination of fresh primary evidence, a quantified share-shrink clock, a visible clinical and regulatory path, and enough balance-sheet support to keep the thesis from depending on one heroic assumption.

What should surprise the reader: A sophisticated reader should not be able to buy a large-cap oncology company at $49.46 when management has already spent $590.6 million buying stock at an average $43.14, plans to finish the old program this month, and now has enough remaining authorization to retire about 7.3% of the current share count, all while the official 2026 revenue guide still excludes any zanzalintinib launch revenue.

Geographic Search Audit

  • U.S. lane screened: Exelixis. Selected.
  • Japan lane screened: Nomura. Real capital return, but the closing mechanism is slower.
  • Broader Asia lane screened: Baidu. Real event calendar, but too much of the valuation bridge still rests on assumptions I did not want to oversell.
  • Europe / UK lane screened: RELX. Strong business and live buyback, but the tape already pays up for quality.
  • If any lane was rejected, why: Japan lost on urgency, broader Asia lost on inference load, and Europe / UK lost on surprise potential relative to valuation.

Why This Is the Best Opportunity Right Now

Exelixis does not need a dramatic macro call. It needs the market to stop pretending that all the value sits inside the current Cabometyx franchise.

The company has already given investors three concrete facts. First, the current business still throws off real cash. Second, management is using that cash to remove stock. Third, the next franchise clock is now tied to dated events, not vague hope. That is a cleaner chain of custody than most biotech rerating stories.

What Should Surprise the Reader

The surprise is not that Exelixis owns an approved oncology franchise. The surprise is how little the current tape charges for the bridge between that franchise and the next one.

The company ended March with $1.43 billion of cash and marketable securities. It expects to complete the remaining $159.4 million of the October 2025 repurchase program in May 2026, and it added another $750 million authorization in May 2026. At today's price, that remaining firepower can retire about 18.4 million shares. On an April 27 base of 251.4 million shares outstanding, that is roughly 7.3% of the company. The guide still excludes zanzalintinib launch revenue. The market is not being asked to believe in fantasy numbers. It is being asked to believe management's own dated roadmap.

The Setup

Exelixis reported a first quarter that looked more like a deliberate bridge than a plateau. Total revenue was $610.8 million. Net product revenue was $555.0 million. Royalty revenue was $45.9 million. GAAP net income was $210.5 million. Non-GAAP diluted EPS was $0.87. The company also kept 2026 total-revenue guidance at $2.525 billion to $2.625 billion. That guide does not include revenue from any potential U.S. launch of zanzalintinib in previously treated metastatic colorectal cancer. [Sources: Exelixis Q1 2026 release and 10-Q.]

This matters because the regulatory and clinical clock is no longer abstract. The FDA is reviewing the zanzalintinib NDA and assigned a December 3, 2026 PDUFA target action date. The planned final analysis for the other dual primary endpoint in STELLAR-303 is expected in mid-2026. Topline results from STELLAR-304 are expected in second half 2026. [Source: Exelixis Q1 2026 release.]

The Mispricing

The market appears to be pricing Exelixis as if Cabometyx is the only asset that deserves hard valuation and everything beyond it is soft optionality.

That is too blunt. The bridge is already visible. The existing business funds repurchases. The repurchases improve per-share math even if operating income stalls. The next set of zanzalintinib milestones is now tied to dates the market can watch. The company does not need a blue-sky pipeline premium to justify a higher stock price. It needs investors to stop treating the bridge as worthless.

Price

EXEL last traded at $49.46 at 18:00 Ho Chi Minh City time on May 13, 2026. The finance snapshot shows a market capitalization of about $13.22 billion, a trailing P/E of about 16.4x, and trailing EPS of $3.02.

Against the company's own capital-allocation record, that price is not demanding:

  • Exelixis had already repurchased 13.7 million shares for $590.6 million under the October 2025 program, at an average price of $43.14 per share.
  • The current price is only about 14.7% above that average buyback cost.
  • The remaining $909.4 million of authorization across the old and new programs equals about 18.4 million shares at today's price.
  • On the April 27 share count of 251,355,083, that potential reduction is about 7.3%.

The market is still offering a live oncology cash generator at a price that leaves management room to keep shrinking the denominator meaningfully.

Positioning

I did not verify live short interest, stock-loan cost, or options-positioning data during this run.

So the positioning claim here is inferential, not measured. The tape still seems to treat Exelixis as a mature oncology franchise whose pipeline deserves little credit until the FDA decision is in hand. That caution is understandable. It also creates the setup. If investors were already willing to capitalize the bridge from Cabometyx cash flow to zanzalintinib approval, the stock would not still look this ordinary against the buyback math.

Missing-data note: direct holder-flow evidence was weaker than the operating, cash-balance, and capital-return evidence in this run.

Catalyst

This is a stacked catalyst calendar, not a one-date gamble.

  1. Exelixis expects to complete the remaining $159.4 million of the October 2025 repurchase program in May 2026.
  2. The board has already authorized an additional $750 million of repurchases through December 31, 2027.
  3. The STELLAR-303 final analysis for the non-liver-metastases population is expected in mid-2026.
  4. STELLAR-304 topline results are expected in second half 2026.
  5. The zanzalintinib NDA carries a December 3, 2026 PDUFA date.

The closing mechanism is straightforward. If the business keeps producing cash, the share count keeps falling. If the clinical and regulatory bridge stays intact, the market eventually has to price more than a static Cabometyx runoff story.

Payoff Map

The cleanest expression is long EXEL common stock. That is not personalized financial advice. It is the simplest wrapper for a thesis built on visible repurchases, dated milestones, and a balance sheet that can support both.

Options are not the lead structure in this note. The catalyst calendar makes options plausible, but I did not verify a live chain with spreads and open interest good enough to make an options-first recommendation.

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff Time Horizon Conditions Required Evidence Quality
Top Case 25% EXEL $66.00 +33.4% 6-12 months The mid-2026 and second-half 2026 zanzalintinib readouts stay supportive, the FDA review stays on track for December, and the market begins to price EXEL as more than a static Cabometyx cash machine while the share count keeps falling. Medium
Base Case 50% EXEL $58.00 +17.3% 3-9 months Exelixis completes the May buyback, sustains 2026 guidance, and the market capitalizes the expected 7%-plus share shrink plus a still-live bridge to the December PDUFA date. High
Bottom Case 25% EXEL $41.00 -17.1% 1 day to 9 months Clinical timing slips, the market decides the zanzalintinib bridge deserves little value, or Cabometyx growth cools enough to offset the buyback benefit. Medium
Invalidation / Stop Condition n/a Sustained break below EXEL $43.00 n/a n/a Fresh evidence shows that the zanzalintinib bridge is materially impaired, the cash engine is weakening, or the board stops acting like the stock is cheap. Medium

Probability-weighted expected value: approximately +12.7%, based on the scenario returns above.

Current market price / level: EXEL $49.46.

Timestamp: 18:00 Ho Chi Minh City time on May 13, 2026.

Primary instrument: EXEL common stock.

Alternative expressions considered: January 2027 call structures tied to the December 3, 2026 PDUFA date, and a wait-for-data approach after mid-2026. Options were rejected as primary because live chain quality was not verified. Waiting for mid-2026 data may give cleaner confirmation, but likely gives up the easiest part of the rerating.

Confidence: Medium.

What Would Prove This Wrong

The thesis breaks if the bridge stops being a bridge.

That can happen three ways. The clinical path disappoints. The regulatory path slips. Or the current business stops throwing off enough clean cash to fund the share shrink without straining the balance sheet. A sustained move below $43.00 on fresh evidence of one of those failures would tell you the market's skepticism was not just caution, it was correct.

Risk Audit

Strongest counterargument: The market may be right that Exelixis is still mostly a single-franchise company, and that it is premature to capitalize zanzalintinib before approval and commercial proof.

Most fragile assumption: That the market will assign meaningful value to the zanzalintinib bridge before the December 2026 FDA decision is resolved.

What the market may already know: Investors know Cabometyx is mature, biotech multiples can stay compressed for long stretches, and pre-approval enthusiasm often fades if timelines slip.

What could make the trade lose money even if the thesis is directionally right: The company could execute the buyback and still see the stock stall if investors keep demanding post-approval proof before rerating the franchise.

Liquidity / execution risks: Common-stock liquidity is solid, but biotech names gap around data and regulatory updates.

Leverage risks: This is not a levered balance-sheet story. The company ended March with about $1.43 billion of cash and marketable securities and no debt load that dominates the thesis.

Information reliability risks: The operating and cash facts are primary-source quality. The weaker area in this run was live positioning data, which was not independently verified.

Invalidation trigger: A sustained break below $43.00 paired with negative regulatory or clinical evidence, or a meaningful deterioration in the cash-generation base.

Publish / revise / reject recommendation: Publish.

Bottom Line

Exelixis is no longer just a one-product valuation problem. It is a dated bridge. The current franchise still generates cash, management is using that cash to retire stock, and the next franchise has visible regulatory and clinical markers that the official revenue guide still excludes. The market is still pricing the first fact and discounting the rest too hard.

Best trade strategy: Long EXEL common stock. Options are secondary only if a live chain is later verified and priced well.

Sources